<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7128473/results/search/test_trace/results.xml">
  <result pre="transplantation represent vulnerable patient cohorts with an increased risk of" exact="infection" post="and/or a severe course of COVID-19. In addition, the"/>
  <result pre="less frequently.1 While symptoms remain mild throughout the course of" exact="infection" post="in the majority of patients, older patients were identified"/>
  <result pre="with advanced chronic liver disease are at increased risk of" exact="infection" post="due to cirrhosis-associated immune dysfunction.4 The same could be"/>
  <result pre="available linking underlying liver diseases with the course of SARS-CoV-2" exact="infection" post="and there are many open questions (Box 1). Chronic"/>
  <result pre="are many open questions (Box 1). Chronic hepatitis B virus" exact="infection" post="for example, which is more prevalent in China than"/>
  <result pre="remains to be determined, but it appears unlikely that SARS-CoV-2" exact="infection" post="causes liver damage to an amount that substantially contributes"/>
  <result pre="these patients. General recommendations and guidelines with regards to prevention," exact="diagnosis" post="and treatment of COVID-19 from local authorities should be"/>
  <result pre="General recommendations and guidelines with regards to prevention, diagnosis and" exact="treatment" post="of COVID-19 from local authorities should be adhered to."/>
  <result pre="of patients with advanced liver disease and those receiving immunosuppressive" exact="treatment" post="is often performed in larger units or centres. These"/>
  <result pre="exposure to medical staff should be minimised wherever possible. Face-to-face" exact="contact" post="is the basis for the physician-patient relationships and allows"/>
  <result pre="the amount of individual contacts, physicians are at risk of" exact="infection" post="and subsequently also dissemination of the virus. Thus, it"/>
  <result pre="not only to attend to COVID-19 patients who stay in" exact="quarantine" post="at home but also to care for patients that"/>
  <result pre="patients that need to be protected from a potentially harmful" exact="infection" post="and guide them through the pandemic, explaining the future"/>
  <result pre="•Use telemedicine or visits by phone wherever possible. •Routine laboratory" exact="testing" post="can be performed locally, e.g. through primary care physician,"/>
  <result pre="risk of a severe course of COVID-19.1 Use telemedicine/local laboratory" exact="testing" post="for follow-up visits in patients under antiviral therapy, send"/>
  <result pre="with compensated cirrhosis, consider delaying hepatocellular carcinoma (HCC) surveillance and" exact="screening" post="for varices. Non-invasive risk assessment for the presence of"/>
  <result pre="be closely followed to prevent decompensation and avoid admission. •Include" exact="testing" post="for SARS-CoV-2 in patients with acute decompensation or ACLF."/>
  <result pre="Specific considerations for patients actively listed for transplantation •SARS-CoV-2 routine" exact="testing" post="should be performed before transplantation in both donors and"/>
  <result pre="before transplantation in both donors and recipients, acknowledging that negative" exact="testing" post="cannot completely rule out infection. •Consent for diagnostic and"/>
  <result pre="Streptococcus pneumoniae and influenza. •In stable patients: perform local laboratory" exact="testing" post="(including drug levels). •We currently advise against reduction of"/>
  <result pre="diagnostic procedures Endoscopy Patients without COVID-19: Depending on available resources," exact="screening" post="for varices by esophagogastroduodenoscopy (EGD) should be reserved for"/>
  <result pre="after careful individual risk-benefit considerations, including risk for nosocomial SARS-CoV-2" exact="infection" post="depending on local COVID-19 burden. Patients with COVID-19: Endoscopic"/>
  <result pre="of unknown aetiology (in case of suspected autoimmune liver disease," exact="treatment" post="without histological diagnosis can be considered based on individual"/>
  <result pre="(in case of suspected autoimmune liver disease, treatment without histological" exact="diagnosis" post="can be considered based on individual risk-benefit considerations) •liver"/>
  <result pre="be deferred in most patients as •treatment/care for COVID-19 outweighs" exact="diagnosis" post="of co-existing liver disease •systemic inflammation associated with COVID-19"/>
  <result pre="others. Thus, we recommend that specialised centres provide easily accessible" exact="contact" post="information for local health care providers to facilitate fast"/>
  <result pre="or other complications. General measures to prevent SARS-CoV-2 exposure and" exact="infection" post="will be of utmost importance for these patients. Depending"/>
  <result pre="outpatient care, we recommend that specialised centres provide easily accessible" exact="contact" post="information to facilitate immediate hepatology consultations. However, due to"/>
  <result pre="the ACE2-receptor mediated endocytosis and is widely used in the" exact="treatment" post="of patients with severe COVID-19 as monotherapy, but also"/>
  <result pre="course of influenza, it is reasonable to assume that early" exact="treatment" post="initiation might also be beneficial to prevent severe pneumonia"/>
  <result pre="course of the disease, we recommend inclusion into early antiviral" exact="treatment" post="programmes or clinical trials that might be active at"/>
  <result pre="1 Selected repurposed drugs that have been suggested/discussed for the" exact="treatment" post="of COVID-19 and considerations for patients with liver disease"/>
  <result pre="cellular receptor ACE224 •Endosomal acidification fusion inhibitor •Generally used for" exact="treatment" post="of malaria and amoebiasis •In vitro and in vivo"/>
  <result pre="available Sofosbuvir∗maybe combination with ribavirin •Nucleotide analogue, RdRp-inhibitor •Approved for" exact="treatment" post="of chronic hepatitis C •In vitro data show binding"/>
  <result pre="is required for S protein priming48 •Licensed in Japan for" exact="treatment" post="of chronic pancreatitis •Patients with chronic viral hepatitis and"/>
  <result pre="ALT elevations typically arising a few weeks after start of" exact="treatment" post="•Risk of reactivation of tuberculosis, pneumocystis jirovecii, herpes zoster"/>
  <result pre="•Minimal hepatic metabolism This list is not intended to give" exact="treatment" post="recommendations. The evidence to use these drugs is low."/>
  <result pre="chronic liver disease and COVID-19 •In patients with decompensated cirrhosis," exact="treatment" post="for cirrhosis-associated complications such as portal hypertension, ascites, hepatic"/>
  <result pre="syndromeLancet Respir Med2020[Epub ahead of print] 6LiX.GengM.PengY.MengL.LuS.Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19J Pharm Anal2020[Epub ahead of print] 7MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: consider"/>
  <result pre="pathogenic human coronavirus infectionsLiver Int2020[Epub ahead of print] 11SchütteA.CiesekS.WedemeyerH.LangeC.M.Influenza virus" exact="infection" post="as precipitating event of acute-on-chronic liver failureJ Hepatol70201979779930635243 12WallsA.C.ParkY.-J.TortoriciM.A.WallA.McGuireA.T.VeeslerD.Structure,"/>
  <result pre="(2019-nCoV) in vitroCell Res30202026927132020029 25de WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
  <result pre="J Med2020 29GaoJ.TianZ.YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends1412020727332074550 30LiG.De"/>
  <result pre="disease 2019 (COVID-19)Drug Discoveries Ther1420205860 32GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt"/>
  <result pre="Drug interactions2020Available from:http://www.covid19-druginteractions.org/ 35[Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumonia]Zhonghua Jie He He Hu Xi"/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol Res Perspect52017e0029328596841 37YoungB.E.OngS.W.X.KalimuddinS.LowJ.G.TanS.Y.LohJ.Epidemiologic features and"/>
  <result pre="J Rheum Dis20201785986928160426 41WHO. Clinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected. 2020. Available from:"/>
  <result pre="Available from: https://www.hep-druginteractions.org/. [Accessed 20 March 2020]. 46RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory diseaseLancet3952020e30e3132032529 47MarkhamA.Baricitinib: first global approvalDrugs77201769770428290136"/>
  <result pre="for a randomized controlled trial on the assessment of camostat" exact="treatment" post="in chronic pancreatitis (TACTIC)Trials20201950131412955 50Press release on planned clinical"/>
 </snippets>
</snippetsTree>
